|
1
|
Shapiro DA, Renock S, Arrington E, Chiodo
LA, Liu LX, Sibley DR, Roth BL and Mailman R: Aripiprazole, a novel
atypical antipsychotic drug with a unique and robust pharmacology.
Neuropsychopharmacology. 28:1400–1411. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Greenaway M and Elbe D: Focus on
aripiprazole: A review of its use in child and adolescent
psychiatry. J Can Acad Child Adolesc Psychiatry. 18:250–260.
2009.PubMed/NCBI
|
|
3
|
Russo E, Citraro R, Davoli A, Gallelli L,
Di Paola ED and De Sarro G: Ameliorating effects of aripiprazole on
cognitive functions and depressive-like behavior in a genetic rat
model of absence epilepsy and mild-depression comorbidity.
Neuropharmacology. 64:371–379. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burda K, Czubak A, Kus K, Nowakowska E,
Ratajczak P and Zin J: Influence of aripiprazole on the
antidepressant, anxiolytic and cognitive functions of rats.
Pharmacol Rep. 63:898–907. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kronenberg G, Gertz K, Heinz A and Endres
M: Of mice and men: Modelling post-stroke depression
experimentally. Br J Pharmacol. 171:4673–4689. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loubinoux I, Kronenberg G, Endres M,
Schumann-Bard P, Freret T, Filipkowski RK, Kaczmarek L and
Popa-Wagner A: Post-stroke depression: Mechanisms, translation and
therapy. J Cell Mol Med. 16:1961–1969. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shimoda K and Kimura M: Two cases of
emotional disorder after middle cerebral artery infarction showing
distinct responses to antidepressant treatment. Neuropsychiatr Dis
Treat. 10:965–970. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim YR, Kim HN, Pak ME, Ahn SM, Hong KH,
Shin HK and Choi BT: Studies on the animal model of post-stroke
depression and application of antipsychotic aripiprazole. Behav
Brain Res. 287:294–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim YR, Kim HN, Hong KW, Shin HK and Choi
BT: Antidepressant effects of aripiprazole augmentation for
cilostazol-treated mice exposed to chronic mild stress after
ischemic stroke. Int J Mol Sci. 18:pii: E3552017. View Article : Google Scholar
|
|
10
|
Cosi C, Waget A, Rollet K, Tesori V and
Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not
haloperidol protect against kainic acid-induced lesion of the
striatum in mice, in vivo: Role of 5-HT1A receptor activation.
Brain Res. 1043:32–41. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, Chen Y, Wu J, Manaenko A, Yang P,
Tang J, Fu W and Zhang JH: Activation of dopamine D2 receptor
suppresses neuroinflammation through αB-crystalline by inhibition
of NF-κB nuclear translocation in experimental ICH mice model.
Stroke. 46:2637–2646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hall ED, Andrus PK, Oostveen JA, Althaus
JS and VonVoigtlander PF: Neuroprotective effects of the dopamine
D2/D3 agonist pramipexole against postischemic or
methamphetamine-induced degeneration of nigrostriatal neurons.
Brain Res. 742:80–88. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koprivica V, Regardie K, Wolff C, Fernalld
R, Murphy JJ, Kambayashi J, Kikuchi T and Jordan S: Aripiprazole
protects cortical neurons from glutamate toxicity. Eur J Pharmacol.
651:73–76. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zaleska MM, Mercado ML, Chavez J,
Feuerstein GZ, Pangalos MN and Wood A: The development of stroke
therapeutics: Promising mechanisms and translational challenges.
Neuropharmacology. 56:329–341. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hua Y, Schallert T, Keep RF, Wu J, Hoff JT
and Xi G: Behavioral tests after intracerebral hemorrhage in the
rat. Stroke. 33:2478–2484. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patil SP, Jain PD, Sancheti JS, Ghumatkar
PJ, Tambe R and Sathaye S: Neuroprotective and neurotrophic effects
of Apigenin and Luteolin in MPTP induced parkinsonism in mice.
Neuropharmacology. 86:192–202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Taleb O, Bouzobra F, Tekin-Pala H, Meyer
L, Mensah-Nyagan AG and Patte-Mensah C: Behavioral and
electromyographic assessment of oxaliplatin-induced motor
dysfunctions: Evidence for a therapeutic effect of
allopregnanolone. Behav Brain Res. 320:440–449. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Farlow MR and Shamliyan TA: Benefits and
harms of atypical antipsychotics for agitation in adults with
dementia. Eur Neuropsychopharmacol. 27:217–231. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kasteng F, Eriksson J, Sennfält K and
Lindgren P: Metabolic effects and cost-effectiveness of
aripiprazole versus olanzapine in schizophrenia and bipolar
disorder. Acta Psychiatr Scand. 124:214–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Citrome L, Kalsekar I, Baker RA and Hebden
T: A review of real-world data on the effects of aripiprazole on
weight and metabolic outcomes in adults. Curr Med Res Opin.
30:1629–1641. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khanna P, Suo T, Komossa K, Ma H,
Rummel-Kluge C, El-Sayeh HG, Leucht S and Xia J: Aripiprazole
versus other atypical antipsychotics for schizophrenia. Cochrane
Database Syst Rev: CD006569. 2014. View Article : Google Scholar
|
|
22
|
Zhu H, Zhang Y, Shi Z, Lu D, Li T, Ding Y,
Ruan Y and Xu A: The neuroprotection of liraglutide against
ischaemia-induced apoptosis through the activation of the PI3K/AKT
and MAPK pathways. Sci Rep. 6:268592016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park SW, Lee CH, Lee JG, Kim LW, Shin BS,
Lee BJ and Kim YH: Protective effects of atypical antipsychotic
drugs against MPP(+)-induced oxidative stress in PC12 cells.
Neurosci Res. 69:283–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shioda N, Sawai M, Ishizuka Y, Shirao T
and Fukunaga K: Nuclear translocation of
calcium/calmodulin-dependent protein kinase IIδ3 promoted by
protein phosphatase-1 enhances brain-derived neurotrophic factor in
dopaminergic neurons. J Biol Chem. 290:21663–21675. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Farber K, Pannasch U and Kettenmann H:
Dopamine and noradrenaline control distinct functions in rodent
microglial cells. Mol Cell Neurosci. 29:128–138. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shao W, Zhang SZ, Tang M, Zhang XH, Zhou
Z, Yin YQ, Zhou QB, Huang YY, Liu YJ, Wawrousek E, et al:
Suppression of neuroinflammation by astrocytic dopamine D2
receptors via αB-crystallin. Nature. 494:90–94. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huck JH, Freyer D, Böttcher C, Mladinov M,
Muselmann-Genschow C, Thielke M, Gladow N, Bloomquist D,
Mergenthaler P and Priller J: De novo expression of dopamine D2
receptors on microglia after stroke. J Cereb Blood Flow Metab.
35:1804–1811. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kato T, Mizoguchi Y, Monji A, Horikawa H,
Suzuki SO, Seki Y, Iwaki T, Hashioka S and Kanba S: Inhibitory
effects of aripiprazole on interferon-gamma-induced microglial
activation via intracellular Ca2+ regulation in vitro. J Neurochem.
106:815–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
